Celgene to apply machine learning to market access

Celgene is set to apply machine learning to market access, commercialisation and drug discovery through a partnership with GNS Healthcare. GNS applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients. The service and license arrangement with Celgene covers its REFS (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform. The deal, which involves Celgene’s second equity investment in the firm, will also see several GNS causal modeling experts brought in-house at the biopharma company’s sites to operate the platform. Iya Khalil, chief commercial officer and co-founder of GNS, said: “Companies that embrace data-driven frameworks and culture such as Celgene are gaining a competitive advantage to rapidly generate insights that are simply not possible with any…


Link to Full Article: Celgene to apply machine learning to market access

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!